OpenAI Meets with FDA on AI-Driven Drug Evaluation

•

3 days ago

Summary

OpenAI and FDA discuss using AI for faster drug evaluations; the goal is to accelerate a small portion of the drug development timeline; AI's reliability remains an open question.

Key Points

OpenAI has met with officials from the U.S. Food and Drug Administration (FDA) to discuss the agency's use of AI to speed up drug evaluations
The project, called cderGPT, aims to accelerate a small portion of the drug development timeline
Despite potential benefits, there are unanswered questions around how to control for the unreliability of AI models

Why It Matters

This collaboration could lead to faster and more efficient drug evaluations, but reliable AI models remain a crucial concern.

Author

Maxwell Zeff

More Headlines

Whitney Wolfe Herd Returns to Lead Bumble After CEO Departure

whitney wolfe herd, the founder of dating app bumble, has returned to lead the company after ceo lidiane jones' sudden departure. in an interview with the new york times, wolve herd spoke about her decision to return and what led to jones' resignation.

TechCrunch AllStage 2025

TechCrunch AllStage 2025 is an event built to answer questions for startup founders. Expect main-stage conversations, deep-dive workshops, and tactical networking designed to help you scale with confidence.

WhatsApp Scores Major Victory Against NSO Group

On Tuesday, WhatsApp scored a major victory against NSO Group. The Israeli-based spyware developer was found guilty of violating privacy laws and developing malware that targeted users.

Ellen Chisa to Speak at TechCrunch All Stage 2025

Ellen Chisa, partner at Boldstart Ventures, will join TechCrunch All Stage 2025 to share her expertise on investing in enterprise startups from day one. She'll discuss what investors are really looking for in the earliest stages of enterprise software and how founders can position themselves for conviction-level backing.

Tumultuous Year for US Semiconductor Industry

In the United States, the semiconductor industry has been facing significant challenges in 2022. The year began with a proposal by former President Joe Biden to impose sweeping new export restrictions on U.S.-made AI chips. This move was aimed at controlling the flow of sensitive technology and preventing its misuse by rival nations like China.

Weekend Bike Rides

Weekend bike rides have been a cherished tradition for the author. They provide a much-needed escape from the hustle and bustle of daily life, allowing time to clear one's mind and recharge. The article highlights the benefits of taking time out for oneself and making the most of weekend bike rides.

OpenAI Leads Enterprise AI Market

OpenAI appears to be pulling ahead of rivals in the race to capture enterprises' AI spend, according to transaction data from fintech firm Ramp. As of April, 32.4% of U.S. businesses were paying for subscriptions to OpenAI AI models, platforms, and tools.

Google Settles Texas Lawsuits Over Privacy Violations

Google has agreed to pay the state of Texas $1.375 billion to settle two lawsuits accusing the company of tracking users' personal location, incognito searches, and voice and facial data without their permission. The lawsuits were brought by Texas Attorney General Ken Paxton in 2022. This is the highest recovery nationwide against Google for any attorney general's enforcement of state privacy laws.

Week in Review: Instacart CEO, OpenAI's Non-Profit Division, and More

Instacart CEO Fidji Simo is joining OpenAI to help the company scale its traditional functions. OpenAI's non-profit division will retain control, and Tesla's Cybercab and Robotaxi trademarks have hit roadblocks.

Ftc Votes to Delay Enforcement of Negative Option Rule

The Federal Trade Commission (FTC) has voted to delay the enforcement of its Negative Option Rule, also known as the 'click-to-cancel' rule. The rule aims to make it easier for consumers to cancel subscriptions by requiring companies to provide a clear and easy way to do so. The FTC delayed the enforcement of some provisions earlier this year, and now it is delaying the enforcement of all provisions by 60 days.

Billy Evans Works on New Startup, Haemanthus

Billy Evans, the partner of disgraced Theranos founder Elizabeth Holmes, is working on a new startup called Haemanthus. The company aims to deliver human health optimization through blood testing and has developed a machine that uses lasers to analyze blood, saliva, and urine samples.

Joint International Law Enforcement Action Shuts Down Botnet

The Department of Justice announced the dismantling of a botnet and the indictment of four individuals accused of profiting from running the botnet. The botnet, which was operated by Anyproxy and 5Socks, used compromised routers to provide anonymity for malicious actors online.

CoreWeave Seeks $1.5 Billion Debt Deal

CoreWeave, a New Jersey-based data center operator, has announced that it is seeking a $1.5 billion debt deal. This comes after the company's IPO was met with disappointing investor interest. The company had initially targeted a $2.7 billion fundraise but was forced to scale back due to concerns over its large debt burden and weakening market for AI infrastructure.

Google and Elementl Power Partner on Nuclear Reactors

Google and Elementl Power announced a partnership to develop three advanced nuclear reactor sites. The deal aims to add at least 600 megawatts of generating capacity at each site, with the option for commercial off-take. This move supports Google's AI ambitions and growing power demands at its data centers.

Microsoft Build: AI-Powered Copilot Takes Center Stage

Microsoft's biggest event, Build, is scheduled to start on May 19. Expect AI-powered copilot products and deep research tools. The keynote will feature Microsoft CEO Satya Nadella and CTO Kevin Scott, who will discuss the company's Copilot family of AI-powered products.